Valepotriate
(Synonyms: 戊曲酯,Valtrate) 目录号 : GC39232
A valepotriate with diverse biological activities
Cas No.:18296-44-1
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Valtrate is a valepotriate that has been found in Valeriana and has diverse biological activities.1,2,3 It inhibits nuclear export of influenza virus ribonucleoprotein complex (vRNP) in HeLa cells when used at a concentration of 3.6 ?M and inhibits influenza virus infection in MDCK cells (IC50 = 0.19 ?M).1 Valtrate is cytotoxic to GLC-4 lung and COLO 320 colorectal cancer cells (IC50s = 1.4 and 3 ?M, respectively).2 It increases the number of entries into, and percentage of time spent in, the open arms of the elevated plus maze, indicating anxiolytic-like activity, and decreases serum corticosterone levels in rats when administered at a dose of 10 mg/kg.3
1.Watanabe, K., Takatsuki, H., Sonoda, M., et al.Anti-influenza viral effects of novel nuclear export inhibitors from Valerianae Radix and Alpinia galangaDrug Discov. Ther.5(1)26-31(2016) 2.Bos, R., Hendriks, H., Scheffer, J.J., et al.Cytotoxic potential of valerian constituents and valerian tincturesPhytomedicine5(3)219-225(1998) 3.Shi, S.-N., Shi, J.-L., Liu, Y., et al.The anxiolytic effects of valtrate in rats involves changes of corticosterone levelsEvid. Based Complement. Alternat. Med.325948(2014)
| Cas No. | 18296-44-1 | SDF | |
| 别名 | 戊曲酯,Valtrate | ||
| Canonical SMILES | O=C(CC(C)C)O[C@@H]1[C@]2(CO2)[C@]([C@@H]3OC(CC(C)C)=O)([H])C(C(COC(C)=O)=CO3)=C1 | ||
| 分子式 | C22H30O8 | 分子量 | 422.47 |
| 溶解度 | Soluble in DMSO | 储存条件 | -20°C, protect from light |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.367 mL | 11.8352 mL | 23.6703 mL |
| 5 mM | 0.4734 mL | 2.367 mL | 4.7341 mL |
| 10 mM | 0.2367 mL | 1.1835 mL | 2.367 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Anti-epileptic Effects of Valepotriate Isolated from Valeriana jatamansi Jones and Its Possible Mechanisms
Pharmacogn Mag 2017 Jul-Sep;13(51):512-516.PMID:28839381DOI:10.4103/0973-1296.211027.
Objective: This work aimed to investigate the anti-epileptic effects of Valepotriate isolated from Valeriana jatamansi Jones and studied its possible mechanisms. Methods: The anti-epileptic effects of Valepotriate were studied using maximal electroshock-induced seizure (MES), pentylenetetrazole (PTZ)-induced epilepsy, and pentobarbital sodium-induced sleeping model in mice. The possible anti-epileptic mechanisms of Valepotriate were investigated by analyzing the expressions of GABAA, GABAB, glutamic acid decarboxylase (GAD65), Bcl-2, and caspase-3 in the brain using Western blot assay. Results: The results indicated that Valepotriate showed significant anti-epileptic activity against MES- and PTZ-induced epilepsy at doses of 5, 10, and 20 mg/kg, and ED50 values for MES- and PTZ-induced epilepsy were 7.84 and 7.19 mg/kg, respectively. Furthermore, Valepotriate (10 and 20 mg/kg) can significantly prolong sleeping time and shorten the latency time on the pentobarbital sodium-induced sleeping time test. Furthermore, Valepotriate (5, 10, and 20 mg/kg) could significantly up-regulate the expression of GABAA, GAD65, and Bcl-2 and down-regulate the expression of caspase-3, but had no significant effect on the expression of GABAB. Conclusion: The results indicated that Valepotriate had anti-epileptic activity and the mechanisms might be associated with regulation of GABA and inhibition of neuronal apoptosis. Summary: Anti-epileptic effect of Valepotriate was investigated for the 1st timeValepotriate showed notable anti-epileptic activityValepotriate can significantly increase the expression of GABAA, glutamic acid decarboxylase 65, and Bcl-2 and reduce the expression of caspase-3.
Three minor Valepotriate isomers from Valeriana jatamansi and their cytotoxicity
J Asian Nat Prod Res 2017 Jan;19(1):15-21.PMID:27924641DOI:10.1080/10286020.2016.1258065.
Three new minor Valepotriate isomers, jatamanvaltrates Z1 (1), Z2 (2), and Z3 (3), have been isolated from the whole plants of Valeriana jatamansi (syn. Valeriana wallichii.). Their structures were elucidated by extensive spectroscopic analysis, especially 2D NMR and ESI-MS/MSn. All isolated compounds displayed moderate cytotoxicity against the lung adenocarcinoma (A549), metastatic prostate cancer (PC-3 M), colon cancer (HCT-8), and hepatoma (Bel7402) cell lines with IC50 values of 2.8-8.3 μM.
A novel derivative of Valepotriate inhibits the PI3K/AKT pathway and causes Noxa-dependent apoptosis in human pancreatic cancer cells
Acta Pharmacol Sin 2020 Jun;41(6):835-842.PMID:32047260DOI:10.1038/s41401-019-0354-1.
Natural compound Valepotriate exhibits inhibitory activity against a number of cancers, but the effect of Valepotriate against pancreatic cancer is unclear, and the structure-activity relationship of Valepotriate has not been characterized. In this study, we performed a structure-based similarity search and found 16 hit compounds. Among the 16 hits, (1S,6S,7R)-6-(acetyloxy)-1-[(3-methylbutanoyl)oxy]-4a,5,6,7a-tetrahydro-1H-spiro[cyclopenta[c]pyran-7,2'-oxiran]-4-ylmethyl 3-methylbutanoate (denoted as Amcp) exhibited superior anticancer activity against human pancreatic cancer BxPC-3 and SW1990 cells. The anti-proliferation activity of Amcp was validated in human pancreatic cancer BxPC-3 and SW1990 cells in vitro. Amcp more effectively induced apoptosis in BxPC-3 and SW1990 cells than gemcitabine. At a concentration of 15 μM, Amcp significantly suppressed the PI3K/AKT pathway and disrupted the mitochondrial membrane equilibrium through modulation of Noxa and Mcl-1 balance in both cell lines. Meanwhile, knockdown of Noxa substantially attenuated Amcp-induced reduction of cell viability and anti-apoptotic protein Mcl-1 level in BxPC-3 cells. In addition, Amcp showed synergistic anticancer effects when combined with gemcitabine in BxPC-3 cells. To conclude, this work not only suggests that Amcp possesses a dual-inhibitory activity towards PI3K/AKT pathway and Mcl-1, but also enlightens further development of bioactive Valepotriate derivatives.
A Valepotriate Fraction of Valeriana glechomifolia Shows Sedative and Anxiolytic Properties and Impairs Recognition But Not Aversive Memory in Mice
Evid Based Complement Alternat Med 2011;2011:720853.PMID:20047889DOI:10.1093/ecam/nep232.
Plants of the genus Valeriana (Valerianaceae) are used in traditional medicine as a mild sedative, antispasmodic and tranquilizer in many countries. This study was undertaken to explore the neurobehavioral effects of systemic administration of a Valepotriate extract fraction of known quantitative composition of Valeriana glechomifolia (endemic of southern Brazil) in mice. Adult animals were treated with a single intraperitoneal injection of Valepotriate fraction (VF) in the concentrations of 1, 3 or 10 mg kg(-1), or with vehicle in the pre-training period before each behavioral test. During the exploration of an open field, mice treated with 10 mg kg(-1) of VF showed reduced locomotion and exploratory behavior. Although overall habituation sessions for locomotion and exploratory behavior among vehicle control and doses of VF were not affected, comparison between open-field and habituation sessions within each treatment showed that VF administration at 1 and 10 mg kg(-1) impaired habituation. In the elevated plus-maze test, mice treated with VF (10 mg kg(-1)) showed a significant increase in the percentage of time spent in the open arms without significant effects in the number of total arm entries. VF at 3 mg kg(-1) produced an impairment of novel-object recognition memory. In contrast, VF did not affect fear-related memory assessed in an inhibitory avoidance task. The results indicate that VF can have sedative effects and affect behavioral parameters related to recognition memory.
Valepotriate content in different in vitro cultures of Valerianaceae and characterization of Valeriana officinalis L. callus during a growth period
Pharm Weekbl Sci 1983 Oct 21;5(5):205-9.PMID:6646985DOI:10.1007/BF02332944.
Different in vitro cultures of Valerianaceae were analysed for Valepotriate content [(iso)valtrate, acevaltrate, didrovaltrate] in a study on properties of production in vitro (plant species, growth conditions, differentiation level, Valepotriate content of the medium after growth). The in vitro cultures were: callus cultures of Valeriana officinalis L., Valerianella locusta L. and Centranthus ruber L.DC.; a suspension culture of Valeriana officinalis L. and a root organ culture of Centranthus ruber L.DC. All of the cultures produced valepotriates in vitro in different amounts. None of the media that had served for growth contained any valepotriates. In order to characterize the in vitro growth more precisely different parameters were analysed at different time intervals during a growth period in one of the cultures (callus culture of Valeriana officinalis L.). These different parameters were: fresh and dry weight, lipid and nitrogen content and (iso)valtrate content. This study during a growth period was performed on two media differing in plant hormone content.